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Interleukin  2  (IL-2,1 formerly termed T  cell growth factor), discovered by Morgan 
et  al.  (1)  is produced by T  lymphocytes after antigen or mitogen stimulation  and is 
required  for the proliferation of activated T  cells. IL-2 is an essential  mediator of the 
immune  response  (2,  3),  and  there  is  preliminary  evidence  that  it  may  also  be 
responsible  for  the  abnormal  cell  proliferation  in  human  lymphoblastic  leukemias 
(4). 2 
Studies  of the mechanism of action of IL-2 using unpurified  or partially  purified 
preparations  have  been  very  difficult,  because  conditioned  media  contain  other 
lymphokines  and  cytokines  with  potent  biological  activities.  Several  groups  have 
reported purification procedures for both murine (5, 6) and human IL-2 (7-9). These 
IL-2 preparations have permitted an increasingly better definition of IL-2 regulation. 
However,  the  purity  of the  human  IL-2  preparations  has  not  always  been  well 
documented. 
In this study, we report a purification procedure of IL-2 which involves chromatog- 
raphy  on  blue  agarose  and  chromatography  on  Procion-red  agarose,  permitting  a 
rapid  purification  of  human  IL-2  to  apparent  homogeneity.  Biochemically,  the 
purified IL-2 appears to be free of any contaminating proteins. Up to three biologically 
active protein components can be detected in sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis  (SDS-PAGE)  gels.  This molecular heterogeneity is dependent  on 
the experimental  conditions used for the IL-2 production. 
Materials  and Methods 
Preparation of Lymphocyte Conditioned  Medium (Ly-CM, Fraction I).  Human lymphocytes (PBL) 
were obtained from peripheral blood of multiple donors (New York Blood Center, New York). 
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In a typical procedure, the cells were initially stimulated by Sendal virus (104 U/ml) as part of 
a  protocol to  induce  interferon.  12  h  later,  the  culture  medium,  rich  in  a-interferon, was 
removed by centrifugation (800 g). The cells were resuspended to 4  ×  10e/ml in serum-free 
RPMI 1640 (Grand Island Biological Co., Grand Island, NY) supplemented with 0.25% bovine 
serum albumin (Sigma Chemical Co., St. Louis, MO) and  1% phytohemagglutinin-M (PHA- 
M)  (Grand  Island  Biological Co.)  and  incubated  at  37°C  for  48  h.  In  some  preparations 
irradiated  (5,000  rad)  Daudi  cells  (106/ml)  were  added  to  the  medium  to  increase  IL-2 
production.  At  the  end  of the  incubation,  cells  and  cell  debris were  separated  from  the 
conditioned medium by centrifugation (10,000  g,  15 min)  and the supernatant was used for 
purification of IL-2. 
Ammonium Sulfate Precipitation (Fraction II).  1683  g of (NH4)2SO4 was added to 3 liters of Ly- 
CM, to achieve 80% saturation. After gentle stirring overnight at 4°C, the precipitate was spun 
down (10,000 g,  15 min), dissolved in 0.05 M  Tris-HC1, pH 7.8, in a  final vol of 100 ml, and 
subsequently dialyzed against 50 vol of 0.05  M  Tris-HCl buffer, pH  7.8,  for 48 h  with five 
changes of the dialyzing buffer. 
Anion-Exchange Chromatography (Fraction III).  The dialyzed concentrate was loaded on a 200- 
ml  column  of DEAE-celluiose  (DE  52,  Whatman,  England)  which  had  been  previously 
equilibrated with 0.05 M Tris-HC1, pH 7.8. The column was washed with the same buffer and 
IL-2 was  eluted  using  a  linear gradient of Tris-buffered NaC1  (0-0.3  M  NaC1)  and  5-ml 
fractions were collected. IL-2-containing fractions were pooled and dialyzed against phosphate- 
buffered saline (PBS), pH 7.2, containing polyethylenglycol (6,000 mol wt)  (PEG 6000;  50%, 
wt/vol) to concentrate pooled fractions. 
Gel Filtration (Fraction IV).  The concentrated DEAE-cellulose preparation was applied to 
AcA 44  Ultrogel  (LKB  Products,  Inc.,  Rockland,  MD)  column  (2.5  ×  90  cm),  previously 
equilibrated with PBS containing 0.1% PEG 6000.  The flow rate was adjusted to 30 ml/h and 
6-ml fractions were collected. IL-2-containing fractions were pooled. The column was calibrated 
with bovine serum albumin (68,000 mol wt), chymotrypsinogen (25,000  mol wt), and ribonu- 
clease A  (14,000  mol wt), all obtained from Pharmacia Fine Chemicals, Div. of Pharmacia, 
Inc., Piscataway, NJ. 
Chromatography on Blue Agarose (Fraction V).  200  ml of the active fractions pooled from the 
AcA 44  Ultrogel column were applied to a  blue agarose (BRL, Gaithersburg, MD)  column 
with a bed vol of 40 ml, previously equilibrated with PBS. A linear gradient of NaC! (0-0.8 M) 
in  PBS was applied and  20-ml fractions were collected. The IL-2-containing fractions were 
pooled and PEG 6000 added to a final concentration of 0.1%  (wt/vol), to stabilize the IL-2. 
Chromatography on Procion-Red  Agarose (Fraction VI).  The pool of active fractions eluted from 
blue agarose was dialyzed against PBS  and  loaded on  a  10  ml  Proeion-red agarose  (BRL) 
column, previously equilibrated with PBS. The column was then washed with PBS and bound 
proteins  were  eluted  by  using  a  stepwise  gradient  of NaCI  in  PBS  with  a  starting  salt 
concentration of 0.3 M  NaCI and a final concentration of 1.0 M  NaC1. 
lsoelectrofocusing.  10 ml of the purified IL-2 were supplemented with 20% glycerol (vol/vol) 
and  2%  Ampholines (vol/vol), pH  3.5-10  (LKB  Products,  Inc.).  A  5-60%  glycerol density 
gradient, containing 0.1% PEG 6000 (wt/vol) and 2% Ampholines, pH 3.5-10, was layered into 
an  isoelectrofocusing column  (LKB  8100).  The  IL-2 sample was applied onto the  isodense 
region of the gradient, followed by focusing for 24 hr at 4°C using a  constant power supply 
(LKB 2103). The terminal voltage was 2,000 V and the terminal current 3-4 mA. 5-ml fractions 
were collected and the pH determined in every fraction. All fractions were dialyzed against 
PBS containing 0.1% PEG 6000 (wt/vol) to remove the bulk of Ampholines and glycerol. The 
IL-2-containing fractions were pooled. 
Protein Assay.  The protein content of samples was measured using the Lowry technique (10). 
For protein concentrations <5 #g/ml, samples were subjected to SDS-PAGE, the protein bands 
were  visualized by  a  modification  of the  silver staining  technique  (11),  and  the  protein 
concentration estimated by comparison with known  amounts of protein standards (soybean 
trypsin inhibitor and a-lactalbumin). Serial dilutions (200 rig-2 ng) of these marker proteins 
were used. 
SDS-PAGE.  The discontinuous Tris-glycine system of Laemmli (12) was used for 1.5 mm- 
thick slab gels using a  5-20%  gradient or a  15%  of acrylamide. The samples were analyzed 456  MOLECULAR HETEROGENEITY OF HUMAN INTERLEUKIN 2 
under both, reduced  (2% SDS, 5% mercaptoethanol)  and nonreduced  (2% SDS) conditions. 
After electrophoresis,  gels were stained  by a silver nitrate method (11). Apparent molecular 
weights  were  determined  using  protein  standards  bovine  serum  albumin  (68,000 mol  wt), 
ovalbumin  (43,000 mol wt),  carbonic anhydrase (30,000 mol wt), soybean  trypsin  inhibitor 
(20,000 mol wt), and a-lactalbumin (14,500 mol wt). After electrophoresis, parallel  gels were 
sliced into  l-ram sections and proteins from each slice were eluted  in 0.3 ml PBS. After 12-18 
h, the eluted  materials were assayed for IL-2 activity. 
Assay for IL-2 activity.  For the IL-2 assay, 4,000 murine IL-2-dependent  cytotoxic T  lym- 
phocyte cells (CTLL) were grown in the presence of log2 dilutions of putative IL-2-containing 
medium in 96-well microtiter  plates (Costar Data Packaging, Cambridge,  MA). The total vol 
in each well was 0.2 ml. 24 h later, 0.5 #Ci of tritiated  thymidine [aH]TdR (20 Ci/mmol sp act; 
New England Nuclear,  Boston, MA) was added to each well. After 4 h, the cells were harvested 
on  glass fiber  strips  and  [aH]dT  incorporation  measured  in  a  liquid  scintillation  counter 
(Packard  Instrument Co., Downers Grove, IL). The IL-2 concentration in the experimental 
sample was then calculated  by probit  analysis (13) using a standard containing 2 U/ml of IL- 
2.  1 U/ml  of IL-2 was  defined  as  the  quantity  of IL-2 released  in  48  h  culture  medium 
conditioned  by rat spleen cells (1 ×  106/ml) stimulated  by concanavalin  A (Con A; 5 #g/ml) 
(13). 
Results 
Purification of IL-2: Evidence for Molecular Heterogeneity Dependent on the Stimuli for Its 
Production.  High levels of IL-2 production were achieved by sequential  stimulation 
of pooled PBL from multiple donors. PBL were first stimulated by Sendai virus for 12 
h. After a change of serum-free culture medium, these cells were restimulated by PHA 
for an additional 48 h. 
Sendai virus or PHA alone stimulated the production of IL-2 at 6-10 U/ml level, 
and sequential stimulation by Sendai  virus and PHA increased IL-2 production to 
50-100  U/ml.  An  additional  increase  in  IL-2  production,  up  to  200  U/ml,  was 
achieved by co-stimulation with Daudi cells. 
A  10-fold concentration of proteins  from  Ly-CM was  achieved  by precipitation 
with ammonium sulfate at 80% saturation. The dialyzed (NH4)2SO4  precipitate was 
placed on a  DEAE-cellulose (DE 52)  column. IL-2 was eluted  with  a  salt  gradient 
from 0-0.3 M  NaCI in 0.05  M  Tris-HC1, pH  7.8, buffer. The IL-2 produced in the 
absence of Daudi cells  eluted  as a  broad peak at  low salt  concentration (0-0.03  M 
NaCI), whereas the IL-2 produced by co-stimulation with Daudi cells  eluted  at salt 
concentrations between 0.03 and 0.08 M NaC1. The bulk of proteins of this preparation 
was eluted at higher salt concentrations (0.1-0.3 M  NaCI). 
The IL-2 eluted from DEAE cellulose was purified further by AcA 44 Ultrogel gel 
filtration. The IL-2 produced in the absence of Daudi cells was eluted in fractions 42- 
52 as a single peak corresponding to a 26,000 mol wt. When IL-2 was produced by co- 
stimulation with Daudi cells,  a  major peak of activity was eluted on fractions 52-66, 
corresponding to a  13,000-18,000 mol wt, whereas a minor peak of activity was found 
at 26,000 mol wt (Fig.  1). The IL-2 activity-containing fractions were pooled. 
The  final  two steps  involved chromatography on  blue  agarose and  Procion-red 
agarose. From the blue agarose column, IL-2 was eluted with 0.5-0.6 M  NaCI in PBS 
and could be clearly separated from a-interferon, which eluted at 0.05-0.4 M  NaCI 
in  PBS  (Fig.  2).  IL-2 was also bound strongly to a  Procion-red agarose column and 
eluted as a  broad peak between 0.6 and 0.9 M  NaC1 in phosphate buffer with peak 
activity in  the  0.7  and  0.8  M  NaC1 eluate  (Fig.  3).  This  broad elution  profile was WELTE,  WANG,  MERTELSMANN,  VENUTA,  FELDMAN,  AND  MOORE  457 
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Fro.  1.  Gel Filtration of IL-2 on AcA 44 Ultrogel. DE 52-purified IL-2 was loaded on a  AcA 44 
Ultrogel  column and  eluted  with  PBS-0.I%  PEG  6000  and  6-ml  fractions were collected.  The 
column was calibrated with bovine serum albumin (68,000 mol wt), chymotrypsinogen (25,000 mol 
wt), and ribonuelease A  (14,000 mol wt). Absorption at  280~.~ (0);  IL 2  (U/ml)  produced in the 
presence (A) or absence (O) of Daudl cells. 
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Fro.  2.  Chromatography of IL-2 on blue agarose. AcA 44 Ultrogel-purified IL-2 was applied to a 
blue agarose column and eluted with a  linear gradient of PBS  (0.05-0.8  M)  and 20-ml fractions 
were collected. Absorption at 280 nm (Q); IL-2 (U/ml) (A), a-interferon (U/ml) (O); NaC1 molarity 
(M)  ([~). 
suggestive of molecular heterogeneity of IL-2. A majority of the other proteins did not 
bind to Procion-red agarose, the rest eluted at low salt concentration. 
The degree of IL-2 purification achieved with the various steps is listed in Table I. 
The  protein  content  of  the  Procion-red  agarose  preparations  was  measured  by 
comparing  the  density  of protein  bands,  visualized  by  silver  staining,  with  serial 
dilutions  of protein  standards  of known  concentrations.  Taking  into  account  the 
limitation of this measurement, an -106 U/mg  protein sp act and a final purification 
of 37,191-fold  were obtained. The overall recovery of IL-2 was  19%. 458  MOLECULAR  HETEROGENEITY  OF  HUMAN  INTERLEUKIN  2 
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FIG.  3.  Chromatography of IL-2 on Proeion-red agarose. The IL-2-containing fractions from blue 
agarose were pooled, and loaded on a Procion-red agarose column. The bound proteins were eluted 
with a  stepwise increase in salt concentration  (0.15-1.0  M  NaCI  in  PBS). Absorption at  280 nm 
(0); IL-2 (U/ml) (A). 
TABLE  I 
Purification  of Human IL-2 
Total  Purifica- 
Fraction  Total protein  activity  Sp act  tion  Yield 
mg  U  U/mg protein  -fold  % 
I  Ly-CM*  10,800  297,000  27  1  100 
II  (NH4)2SO4  precipitate  9,000  247,000  27  84 
III  DEAE cellulose (DE 52)  135  183,000  1,356  50  62 
IV  AcA 44 Uhrogel  40  145,000  3,625  135  49 
V  Blue agarose  0.96  87,680  91,333  3,382  30 
VI  Procion-red agarose  0.055:1:  55,229  1,004,164  37,191  19 
* The IL-2 activity in the Ly-CM was 100 U/ml. 
:~ Protein concentration was determined by comparison of the protein content in the samples with known 
amounts of protein standards (Material and Methods). 
The final preparations obtained after blue agarose chromatography and Procion- 
red agarose chromatography were analyzed on a  5-20% gradient gel followed by the 
highly sensitive silver staining method as shown in Fig 4. It is evident that the Procion- 
red agarose step significantly reduced  contaminating proteins  (Fig.  4 b  and 4 c). In 
addition,  the molecular heterogeneity of IL-2 was apparent,  and this heterogeneity 
was dependent on the stimuli employed for its production. When IL-2 was produced 
in the absence of Daudi  cells,  the purified IL-2 showed only two active bands with 
16,000  and  17,000  mol wt (Fig. 4 c) under both reducing and nonreducing conditions. 
When Daudi cells were used as a co-stimulator for IL-2 production, one active protein 
band with  a  14,500  mol wt was observed (Fig.  4 d).  It  is of interest  to note that  if 
suboptimum concentrations  of Daudi  cells  (<5  ×  105/ml)  were used,  three protein 
bands  with  14,500,  16,000,  and  17,000  real  wt  were  found  (data  not  shown).  To 
obtain a  better resolution, the purified IL-2 was also analyzed on a  15% acrylamide 
gel. After staining, a similar molecular weight pattern was obtained as in the gradient 
gel. A  parallel  gel was sliced  into  1-mm sections, and proteins  from each slice were 
eluted in PBS. IL-2 activity was found to be localized in slice numbers corresponding WELTE, WANG, MERTELSMANN, VENUTA,  FELDMAN, AND MOORE  459 
FIo. 4.  SDS-PAGE  of blue agarose and Procion-red agarose-purified IL-2. IL-2 was treated with 
2% SDS and 5 mM 2-mercaptoethanol and applied to a 5-20% gradient gel. The protein bands 
were visualized by a silver nitrate method. The following  marker proteins (200 ng each) were used: 
ovalbumin (43,000 mol wt), carbonic anhydrase (30,000 mol wt), soybean trypsin inhibitor (20,000 
mol wt) and 0t-lactalbumin (14,500 mol wt). (a) protein standards; (b) blue agarose-purified IL-2 
produced in the absence of Daudi cells; (c)  Procion-red agarose-purified IL-2 prepared  in the 
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FIo.  5.  SDS-PAGE  of Procion-red agarose-purified IL-2 produced in the presence or absence of 
Daudi cells. The IL-2 preparations were treated with 2% SDS and 5 mM 2-mercaptoethanol and 
applied to a  15% polyacrylamide gel. After electrophoresis, the gel was sliced into 1-mm sections 
and proteins eluted with 0.3 ml PBS. The eluted material was assayed for 1L-2 activity. The arrows 
indicate the position of the protein standards soybean trypsin inhibitor (20,000) and a-lactalbumin 
(14,500 tool wt). IL-2 (U/m)) produced in the presence (A) or absence (O) of Daudi cells. 
to  16,000 and 17,000 mol wt (Fig. 5) in IL-2 produced in the absence of Daudi cells, 
and in the  slice number corresponding to  14,500  mol wt  in IL-2  produced  in the 
presence of Daudi cells (Fig. 5). Re-eleetrophoresis of the proteins present in each slice 
with IL-2 activity showed one single band with molecular weight identical to that of 
the eluted band (data not shown). 
The purified IL-2 was subjected to isoelectrofocusing (IEF) analysis using Ampho- 
lines  with  a  broad  pH  range  (pH  3.5-10).  The  IL-2  obtained  without  Daudi 
costimulation was  focused with  an isoelectrie point of ~6.7  (Fig.  6).  An isoelectric 
point of ~8.1  was found if PBL were stimulated in the presence of Daudi cells. The 
yield of IL-2 from the IEF column was ~30%. 
The purified IL-2 did not bind either to Con A or wheat germ agglutinin column. 
Neuraminidase treatment of IL-2 did not affect its biological activity or its molecular 
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was  prepared  by  loading a  5-60%  glycerol density gradient  containing  2%  Ampholines of pH 
3.5-10.  Purified IL-2 was supplemented with 2% Ampholines (pH 3.5-10)  and 20%  glycerol and 
was layered onto the isodense region of the column gradient. A constant power was then applied to 
the column with a  terminal voltage of 2,000 V  and a current of 3-4 mA (24 h, 4°C). pH gradient 
(0); IL-2 (U/ml) produced in the presence of (A) or absence (O) of Daudi cells. 
Biological Activity of Purified IL-2.  The mitogenicity on normal PBL, the capacity 
to  support  the  growth  of  murine  and  human  CTLL,  and  the  presence  of other 
cytokines were  studied  in  the  purified  IL-2.  To  test  for the  presence of PHA,  the 
mitogenicity of the IL-2 preparations was studied on normal PBL. The purified IL-2 
was completely free of mitogenic activity.  It  very actively supported  the  long-term 
growth of human and murine CTLL lines. It is of interest that human CTLL appear 
to require -  10 U/ml purified IL-2 for their optimum growth, whereas murine CTLL 
are maximally stimulated at 2 U/ml. The purified IL-2 contained no detectable a- or 
"/-interferon,  granulocyte-macrophage colony-stimulating  factor  (GM-CSF),  T  cell- 
replacing factor (TRF), B cell growth factor (BCGF), and thymocyte-differentiating 
activity. 
Discussion 
Ly-CM harvested after sequential stimulation of PBL with Sendai virus and PHA, 
and co-stimulation with Daudi cells, showed an IL-2 concentration of 100-200 U/ml. 
It was possible, therefore, to obtain a  high IL-2 concentration in the absence of the 
commonly used tumor promoter phorbol myristic acetate (14). 
The purification procedure presented in this paper introduces the chromatography 
on blue agarose and on Procion-red agarose as two new purification steps for IL-2. 
The binding of IL-2 to these dyes is likely a result of the electrostatic or hydrophobic 
interactions.  The use of these two steps permitted a  37,000-fold purification of IL-2 
from medium conditioned  in  the  presence of 0.25%  bovine serum albumin,  with  a 
19% overall recovery of IL-2 activity. All other purification methods, for both murine 
and human IL-2, have achieved neither a specific activity nor a  yield comparable to 
those described here. Our purification procedure also avoided time-consuming steps. 
This has made our procedure very useful for large-scale purification of IL-2. WELTE, WANG, MERTELSMANN, VENUTA, FELDMAN, AND MOORE  461 
Lymphokines and other regulator molecules such as interleukin  1 (IL-1, formerly 
termed lymphocyte-activating factor) (15), a- or y-interferon (K. Welte, unpublished 
observation;  B.  Rubin,  personal  communication),  TRF  (K.  Welte  and  P.  Ralph, 
unpublished observation), and GM-CSF  (16)  have different capabilities of forming 
hydrophobic interactions. We have exploited these properties to separate IL-2 from 
other  lymphokines  and  factors,  which  contaminate  most  partially  purified  IL-2 
preparations.  For example, a-interferon co-purified with IL-2 during ion-exchange 
chromatography and gel filtration steps, but was clearly separated from IL-2 by blue 
agarose chromatography (Fig. 2). After chromatography on Procion-red agarose, the 
IL-2 preparation did not contain any detectable interferon (a or y), GM-CSF, TRF, 
BCGF, or thymocyte-differentiating activities. In addition, the Procion-red agarose- 
purified IL-2 appeared to be free of any contaminating proteins (Fig. 4). 
Native IL-2 has been previously shown to exist in several molecular forms (7-9). 
Here, we show that the stimuli used for IL-2 induction by PBL can be responsible for 
this heterogeneity. IL-2 produced in the presence or absence of Daudi cells exhibited 
14,000 and 26,000 mol wt, respectively, by gel filtration (Fig. 1). Both molecular forms 
could be obtained by varying the concentration of co-stimulator cells.  These results 
would offer an explanation for the molecular weight differences reported by Mier and 
Gallo (7) and Gillis et al.  (8).  These are most likely a  result of different methods of 
IL-2 induction. 
After denaturation by SDS, the 26,000-mol wt IL-2 exhibited a  molecular weight 
of  16,000-18,000  mol  wt  by  gel  filtration  (data  not  shown).  SDS-PAGE  of this 
denatured  form  demonstrated  the  presence of two  active bands  with  16,000  and 
17,000 mo| wt, respectively. These results together with those of Caplan  et al.  (17) 
indicate  that  after  SDS  denaturation,  human  and  murine  IL-2  exhibit  similar 
molecular weights. The molecular weight of human IL-2 produced in the presence of 
Daudi cells was not  affected by SDS denaturation.  It appears  that  IL-2 activity is 
present in a polypeptide of 14,000-17,000 mol wt in all species studied thus far (8,  18, 
19).  It is not certain if the different molecular forms observed in this have different 
functions,  such  as  preferential  stimulation  of T  cell  subsets.  It  is  also  not  known 
whether the same T  cell will switch its IL-2 synthesis from 26,000 d to 14,000  tool wt 
upon co-stimulation by Daudi  cells, or whether different T  cell subsets are indeed 
responsible for the release of IL-2 in  two molecular forms. If two functional T  cell 
subsets are involved, one subset would produce the 26,000-mol wt IL-2 in response to 
PHA alone, whereas the second subset would require PHA as primary stimulus and 
co-stimulation by Daudi cells as a second signal for the production of 14,000 mol wt 
IL-2. Daudi cells express HLA-DR antigens and Fc receptors. Both of these surface 
molecules have been implicated in the augmentation of the IL-2 response (20,  21). 
The effect of Daudi  cells on  the  IL-2  response,  however, does  appear to be more 
complicated than previously suggested  (20, 21) in view of (a) the shift in mol wt of 
IL-2 from  26,000  to  14,000  induced  by Daudi  cells,  (b)  the  augmentation  of IL-1 
independent IL-2 production as seen in the human lymphoblastic cell line Jurkat, 2 
and  (c)  the  superinduction  of IL-2  in  human  lymphoblastic leukemic  cells by co- 
stimulation  with  Daudi  cells.  2  The  possibility  that  different  T  cell  subsets  are 
responsible for the production of the two IL-2 forms is supported by recent reports on 
the molecular weights of IL-2 produced by human leukemic cells. We have previously 
reported that non-T non-B lymphoblastic leukemias produce the 26,000-mol wt form 462  MOLECULAR  HETEROGENEITY  OF  HUMAN  INTERLEUKIN  2 
of IL-2 after PHA stimulation,  2 whereas Friedman et al.  (22)  recently reported that 
cells obtained from a  patient with T  cell chronic lymphocytic leukemia, stimulated 
under identical conditions, released the  14,000-tool wt form of IL-2. This molecular, 
and possibly functional, heterogeneity of IL-2 observed here are not unique because 
other cytokines, such as GM-CSF, have been shown to exhibit different molecular 
characteristics, dependent on the producer cell type, and these factors were also shown 
to exert preferential effects on subsets of the granulocyte-macrophage cell lineage (16). 
The reason for the molecular heterogeneity of the SDS denatured and native IL-2 
remains to be explored. A variable degree of glycosilation may provide an explanation 
of this phenomenon (9, 23). Robb et al.  (9) have shown that neuraminidase, glycosi- 
dases, and inhibitors of glycosilation can reduce the heterogeneity of IL-2 produced 
by tonsil lymphocytes. However, neuraminidase treatment of IL-2 did not affect its 
molecular weight. In addition, IL-2 failed to bind to immobilized lectins (Con A and 
wheat germ agglutinin), which was in agreement with a previous report by Mier and 
Gallo (7). 
The purification steps described in this study produced IL-2 with an -10  n U/mg 
protein sp act. Because the lowest tool wt of an active IL-2 polypeptide was  14,500, 
it could be calculated that  1 U/ml of IL-2 was equivalent to a  molar concentration 
of 7 ×  10  -xl M. An IL-2 concentration of 1.4 ×  10  -aa M, or ~4 ×  105 molecules/cell, 
was  required  for one-half maximum  stimulation  of murine  CTLL.  Similar  values 
have been reported by Mizel and Mizel (15) for IL-1 on T  cells. 
The highly purified IL-2 is now used in this laboratory to investigate the biological 
effects of IL-2, both in vitro and in vivo. In preliminary experiments, we were able to 
restore, in vitro, the response of T  cells of a patient with Nezeloff's syndrome in both 
the  allogeneic  mixed  lymphocyte  reaction  and  in  cell-mediated  lympholysis  by 
addition  of purified IL-2  (N.  Flomenberg, K. Welte, and  R.  Mertelsmann,  unpub- 
lished observations). In addition, suppressed mitogen response of T  cells from several 
patients with various immunodeficiency syndromes (combined variable immunode- 
ficiencies, Kaposi's sarcoma, and advanced Hodgkin's disease)  could be restored, in 
vitro, to near normal values by addition of purified IL-2 (N. Ciobanu, G. Kruger, and 
K. Welte, manuscript in preparation). A phase I clinical trial using this purified IL-2 
has been initiated. These studies should contribute to the understanding of normal 
human lymphocyte function, immunodeficiency syndromes, and the pathophysiology 
of human lymphoblastic leukemias  (4). 2 
Summary 
Interleukin  2  (IL-2), produced with and  without  co-stimulation by the  Burkitt's 
lymphoma  line  Daudi,  was  purified  37,000-fold  to  apparent  homogeneity  from 
lymphocyte conditioned medium by (NH4)2SO4 precipitation, DEAE-cellulose ion- 
exchange chromatography, gel filtration, and chromatography on blue agarose and 
on Procion-red agarose. The purified IL-2 showed a  106 U/mg protein sp act. IL-2 
produced in the absence of Daudi cells had a  mol wt of 26,000 as measured by gel 
filtration and an isoelectric point of 6.7. This IL-2 showed a  16,000 and 17,000 mol wt 
in  sodium  dodecyl  sulfate-polyacrylamide  gel  electrophoresis  (SDS-PAGE).  IL-2, 
produced in the presence of Daudi  cells  (106/ml), showed a  mol wt of-14,000, as 
measured by both gel filtration and SDS-PAGE, and an isoelectric point of 8.1. The 
purified IL-2 lacked detectable interferon (c~ and y), granulocyte-macrophage colony- WELTE, WANG, MERTELSMANN,  VENUTA,  FELDMAN, AND MOORE  463 
stimulating  factor,  B  cell  growth  factor,  T  cell-replacing  factor,  and  thymocyte- 
differentiating activity and was free of any contaminating proteins as judged by silver 
staining in SDS-PAGE. All three molecular forms of IL-2 were biologically active at 
concentrations  of  10-11-10  -l°  M,  supporting  the  growth  of  human  and  murine 
cytotoxic T  cell lines. 
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